Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Gastrointestinal 1CNS 1

Conditions

Glioblastoma 40Glioma 17Brain Neoplasms 14Astrocytoma 11Neuroblastoma 10Gliosarcoma 10Neoplasms 8Sarcoma, Ewing 7Rhabdomyosarcoma 6Recurrence 5Oligodendroglioma 5Sarcoma 4Medulloblastoma 4Neoplasm Metastasis 3Diffuse Intrinsic Pontine Glioma 3Wilms Tumor 2Small Cell Lung Carcinoma 2Pancreatic Neoplasms 2Osteosarcoma 2Melanoma 2Lymphoma, Follicular 2Hepatoblastoma 2Central Nervous System Neoplasms 2Spinal Cord Neoplasms 1Somatostatinoma 1Rhabdoid Tumor 1Refractory Solid Tumors 1Pyloric Stenosis, Hypertrophic 1Prostatic Neoplasms 1Pheochromocytoma 1

Interventions

pembrolizumab 57Nivolumab 50Ipilimumab 31Specimen Handling 23Magnetic Resonance Spectroscopy 19Cyclophosphamide 14Biopsy 11fludarabine 10binimetinib 10Opdualag 10trametinib 9relatlimab 9Radiosurgery 9CTLA-4 Antigen 9dabrafenib 8lifileucel 7fludarabine phosphate 7aldesleukin 7encorafenib 6Interleukin-2 6cemiplimab 5atezolizumab 5Paclitaxel 5Blood Specimen Collection 5X-Rays 4Taxes 4Pemetrexed 4Gemcitabine 4Cisplatin 4Carboplatin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Melanoma × Temozolomide × 90 days × Clear all
NCT07492680 2026-05-29

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Bristol-Myers Squibb

Phase 2 Not yet recruiting
260 enrolled
CNSDermatologicGastrointestinal

Brain Neoplasms, Melanoma, Pancreatic Neoplasms

NCT06624644 2026-04-22

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

Linnaeus Therapeutics, Inc.

Phase 2/3 Recruiting
135 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡